Bozitinib plus chemo for MET-altered lung cancer after surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests bozitinib combined with chemotherapy to improve outcomes for patients with a specific type of lung cancer (called MET-altered) after surgery. It aims to see if this combination can help prevent the cancer from coming back in people with stage II to IIIA lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have non-small cell lung cancer with a MET gene change (like MET exon 14 skipping or MET amplification).
- You must have had surgery to remove the cancer, and be recovering well.
- You must not have had any previous cancer treatment with medication.
- You must have good enough lung function for surgery.
- You must not have other treatable gene changes like EGFR, ALK, or ROS1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called vebreltinib before surgery for people with a specific type of lung cancer (MET exon 14 skipping mutation) that is at a stage where it can be removed. The goal is to see if the drug can shrink the tumor before surgery, making the operation more successful.
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
This trial tests a combination of a targeted drug (Glumetinib) and chemotherapy (nab-docetaxel) against chemotherapy alone for people with advanced non-small cell lung cancer that has a high level of a protein called MET. It may offer a new option after standard immunotherapy and platinum chemo have stopped working.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests a drug called Vebreltinib given before surgery for non-small cell lung cancer that has a specific change in the MET gene. The goal is to see if it can shrink tumors and make surgery more effective.
Hear when a new MET Exon 14 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.